Le Lézard
Classified in: Business
Subject: STR

Canadian Investment Regulatory Organization Trade Resumption - XYBN


VANCOUVER, BC, Nov. 16, 2023 /CNW/ - Trading resumes in:

Company: Xybion Digital Inc. 

TSX-Venture Symbol: XYBN 

All Issues: Yes

Resumption (ET): 1:30 PM 

CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Canadian Investment Regulatory Organization (CIRO) ? Halts/Resumptions


These press releases may also interest you

at 07:22
Tiger Brokers (HK) officially launches virtual asset trading services, leading the way in Hong Kong's online brokerage industry
Tiger Brokers (HK) ("Tiger Brokers (HK)" or "Tiger...

at 07:17
NAPCO Reports Record Revenues, Net Income and Adjusted EBITDA* for Q3 of Fiscal 2024
NAPCO Security Technologies, Inc. , one of the leading manufacturers and designers of high-tech...

at 07:15
Flow Capital Announces Repayment of USD 4.5 Million Investment
Flow Capital Corp. ("Flow Capital"), a leading provider of flexible growth capital solutions, is pleased to announce the full repayment of a USD 4.5 million investment in an environmental solutions provider. Flow Capital continues to focus on...

at 07:10
bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events
bluebird bio, Inc. announced today that it will host a conference call to discuss first quarter 2024 results and business updates on May 9, at 8:00 a.m. ET. To participate in the conference call, please dial +1 (800) 715-9871 (U.S. and Canada) and...

at 07:05
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. , a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2024 and...

at 07:00
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Total 1Q 2024 net product revenue of $75.0 million, representing 160% year-over-year growth Auvelity® 1Q 2024 net product sales of $53.4 million, representing 240% year-over-year growth Sunosi® 1Q 2024 net product revenue of $21.6 million...

More news about Business...


News published on and distributed by: